Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Feb;61(2):327–329. doi: 10.1038/bjc.1990.64

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.

O Mogensen 1, B Mogensen 1, A Jakobsen 1
PMCID: PMC1971406  PMID: 2310684

Abstract

A tumour-associated trypsin inhibitor (TATI) and the cancer antigen 125 (CA 125) were measured pre- or peroperatively in 30 patients with mucinous ovarian tumours (10 malignant, two borderline and 18 benign) to investigate the separate and combined use of the two markers as a diagnostic tool. In the malignant and borderline cases considered as a whole, TATI was elevated in 83% and CA 125 in 50%. The former marker was increased in one (6%) benign tumour and the latter in another (6%). The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours. The specificity was 89% and the positive predictive value 86%. In conclusion, in the distinction of malignant and borderline mucinous ovarian tumours from benign ones TATI was a more reliable tumour marker than CA 125. The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours in the present series.

Full text

PDF
327

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  3. Bertelsen K., Hansen M. K., Pedersen P. H., Larsen G., Nyland M., Jacobsen M., Andersen J. E. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer. Br J Obstet Gynaecol. 1988 Dec;95(12):1231–1236. doi: 10.1111/j.1471-0528.1988.tb06811.x. [DOI] [PubMed] [Google Scholar]
  4. Fasquelle D., Villemain D., Meffre G., Agnius-Delord C. Dosage du marqueur tumoral CA 125 dans les cancers de l'ovaire: comparaison des méthodes immunoenzymatique et immunoradiométrique. Pathol Biol (Paris) 1988 Mar;36(3):225–229. [PubMed] [Google Scholar]
  5. Finkler N. J., Benacerraf B., Lavin P. T., Wojciechowski C., Knapp R. C. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol. 1988 Oct;72(4):659–664. [PubMed] [Google Scholar]
  6. Haglund C., Huhtala M. L., Halila H., Nordling S., Roberts P. J., Scheinin T. M., Stenman U. H. Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer. 1986 Aug;54(2):297–303. doi: 10.1038/bjc.1986.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Halila H., Huhtala M. L., Haglund C., Nordling S., Stenman U. H. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer. 1987 Aug;56(2):153–156. doi: 10.1038/bjc.1987.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Halila H., Lehtovirta P., Stenman U. H. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer. Br J Cancer. 1988 Mar;57(3):304–307. doi: 10.1038/bjc.1988.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Huhtala M. L., Kahanpä K., Seppälä M., Halila H., Stenman U. H. Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer. 1983 Jun 15;31(6):711–714. doi: 10.1002/ijc.2910310606. [DOI] [PubMed] [Google Scholar]
  10. Koelma I. A., Nap M., Rodenburg C. J., Fleuren G. J. The value of tumour marker CA 125 in surgical pathology. Histopathology. 1987 Mar;11(3):287–294. doi: 10.1111/j.1365-2559.1987.tb02633.x. [DOI] [PubMed] [Google Scholar]
  11. Macdonald F., Bird R., Stokes H., Russell B., Crocker J. Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours. J Clin Pathol. 1988 Mar;41(3):260–264. doi: 10.1136/jcp.41.3.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maughan T. S., Fish R. G., Shelley M., Jasani B., Williams G. T., Adams M. Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary. Gynecol Oncol. 1988 Jul;30(3):342–346. doi: 10.1016/0090-8258(88)90248-x. [DOI] [PubMed] [Google Scholar]
  13. Mogensen O., Mogensen B., Jakobsen A. CA 125 in the diagnosis of pelvic masses. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1187–1190. doi: 10.1016/0277-5379(89)90413-6. [DOI] [PubMed] [Google Scholar]
  14. Mogensen O., Mogensen B., Jakobsen A., Sell A. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation. Eur J Cancer Clin Oncol. 1988 Dec;24(12):1835–1837. doi: 10.1016/0277-5379(88)90094-6. [DOI] [PubMed] [Google Scholar]
  15. Neunteufel W., Breitenecker G. Immunhistochemische Darstellung von CA 125, CA 19-9 und CEA in normalen und pathologisch veränderten Adnexen. Geburtshilfe Frauenheilkd. 1988 May;48(5):334–337. doi: 10.1055/s-2008-1035986. [DOI] [PubMed] [Google Scholar]
  16. Stenman U. H., Huhtala M. L., Koistinen R., Seppälä M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer. 1982 Jul 15;30(1):53–57. doi: 10.1002/ijc.2910300110. [DOI] [PubMed] [Google Scholar]
  17. Vergote I. B., Børmer O. P., Abeler V. M. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987 Jul;157(1):88–92. doi: 10.1016/s0002-9378(87)80352-6. [DOI] [PubMed] [Google Scholar]
  18. van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988 Jul;30(3):307–312. doi: 10.1016/0090-8258(88)90244-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES